About Us
About Navitor Pharmaceuticals

Selectively targeting mTORC1 activation pathways:
An unprecedented and powerful therapeutic approach to address unmet needs in age-related diseases and certain rare disorders

With increasing life expectancy, the need to address chronic diseases that affect long-term health in aging populations is expanding. mTORC1 (mechanistic target of rapamycin complex 1) is a protein kinase complex that has been shown to be a central regulator of cellular aging processes and has been directly implicated in multiple diseases associated with its dysregulation. Our proprietary drug development approach selectively targets the activation of mTORC1 and offers an entirely new treatment approach for a broad range of chronic age-related diseases as well as several rare diseases that are linked to the genetic dysregulation of mTORC1 activation. Our aim is to discover and develop new medicines that restore normal activity to mTORC1 and improve human health.

Navitor’s proprietary drug discovery platform is built on new insights into the activation of mTORC1

Navitor’s drug discovery platform leverages proprietary intellectual property and know-how related to key targets within the cellular pathways required for the activation of mTORC1 as well as their fundamental role in age-related disease processes. Navitor was founded based on groundbreaking discoveries related to the mTORC1 pathway and the role of nutrient signaling, as well as other cellular mechanisms in the regulation of its activation, by the company’s scientific founder, Dr. David Sabatini, MD, PhD, at the Whitehead Institute for Biomedical Research. Dr. Sabatini’s work was instrumental in the discovery of the mTOR kinase and its two multi-protein complexes, mTORC1 and mTORC2, each of which mediates distinct aspects of the mTOR signaling network.

We are applying our technology to develop novel product candidates for age-related and genetic rare diseases

Navitor’s technology is applicable to a wide range of diseases that have been correlated with aging in which nutrient signaling and other cellular mechanisms that drive the activation of the mTORC1 pathway are dysregulated. Navitor’s approach is to selectively “turn up” or “turn down” these cellular pathways to restore normal activity of mTORC1. By selectively targeting the activation of the mTORC1 pathway, Navitor is creating a new class of therapeutics designed to rebalance these signals and restore the normal functional activity of mTORC1 to address the underlying biology of multiple age-related and genetic rare diseases.

World-class team and proprietary technology positioned for successful drug development

Navitor is led by an experienced management team and a world-class scientific advisory board with a proven track record for discovering groundbreaking drugs and building successful drug development companies. The company’s founding intellectual property is based on the scientific work of Dr. David Sabatini at the Whitehead Institute. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Innovation–JJDC, SR One, and The Longevity Fund.

By selectively targeting mTORC1 activation pathways, we believe we will be able to impact chronic disease processes of aging to improve human health.
Download our corporate fact sheet